The effects of digoxin on heart failure mortality and re-admission in a single center cross-sectional study.

IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS

Journal of Cardiovascular and Thoracic Research Pub Date : 2024-01-01 Epub Date: 2024-09-20 DOI:10.34172/jcvtr.33062

Mahsa Behnemoon, Zahra Borumandkia

{"title":"The effects of digoxin on heart failure mortality and re-admission in a single center cross-sectional study.","authors":"Mahsa Behnemoon, Zahra Borumandkia","doi":"10.34172/jcvtr.33062","DOIUrl":null,"url":null,"abstract":"Introduction: Mortality benefit of digoxin prescription in patients suffering from heart failure has been questioned many time. We evaluated these effects among admitted symptomatic heart failure patients.Methods: We retrospectively divided our patients into two groups: group A (n=205) were digoxin prescribed, and group B (n=96) were digoxin naïve patients. Both groups' medical records were gathered for one year, and the study endpoints were compared between the two groups.Results: The mean age was 62.3±12.1 years and 54.8 % were male. All-cause mortality and readmission occurred in 26.7% and 31.7% of individuals, respectively, without significant differences between the two groups. However, in subgroup analysis, there was a significant relationship between in-hospital mortality and the presence of cardiovascular risk factors.Conclusion: Digoxin might increase in-hospital mortality in patients with underlying cardiovascular risk factors.","PeriodicalId":15207,"journal":{"name":"Journal of Cardiovascular and Thoracic Research","volume":"16 3","pages":"194-197"},"PeriodicalIF":1.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489635/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular and Thoracic Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/jcvtr.33062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Mortality benefit of digoxin prescription in patients suffering from heart failure has been questioned many time. We evaluated these effects among admitted symptomatic heart failure patients.

Methods: We retrospectively divided our patients into two groups: group A (n=205) were digoxin prescribed, and group B (n=96) were digoxin naïve patients. Both groups' medical records were gathered for one year, and the study endpoints were compared between the two groups.

Results: The mean age was 62.3±12.1 years and 54.8 % were male. All-cause mortality and readmission occurred in 26.7% and 31.7% of individuals, respectively, without significant differences between the two groups. However, in subgroup analysis, there was a significant relationship between in-hospital mortality and the presence of cardiovascular risk factors.

Conclusion: Digoxin might increase in-hospital mortality in patients with underlying cardiovascular risk factors.

查看原文本刊更多论文

一项单中心横断面研究显示，地高辛对心力衰竭死亡率和再入院率的影响。

导言心力衰竭患者服用地高辛可降低死亡率，这一点曾多次受到质疑。我们对入院的无症状心衰患者进行了评估：我们回顾性地将患者分为两组：A 组（205 人）为地高辛处方患者，B 组（96 人）为地高辛无处方患者。收集两组患者一年的病历资料，比较两组患者的研究终点：平均年龄为（62.3±12.1）岁，54.8%为男性。全因死亡率和再入院率分别为 26.7% 和 31.7%，两组之间无明显差异。然而，在亚组分析中，院内死亡率与是否存在心血管风险因素之间存在显著关系：结论：地高辛可能会增加存在潜在心血管风险因素的患者的院内死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊